Alejandro A. Inclan

Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial

J. Hainsworth, H. Burris, D. Yardley, 2014, Breast Cancer Research and Treatment.